Eli Lilly and Co
NYSE:LLY
Intrinsic Value
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one LLY stock under the Base Case scenario is 342.38 USD. Compared to the current market price of 745.95 USD, Eli Lilly and Co is Overvalued by 54%.
Valuation Backtest
Eli Lilly and Co
Run backtest to discover the historical profit from buying and selling LLY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Eli Lilly and Co
Current Assets | 25.7B |
Cash & Short-Term Investments | 2.9B |
Receivables | 11.3B |
Other Current Assets | 11.5B |
Non-Current Assets | 38.3B |
Long-Term Investments | 3.1B |
PP&E | 12.9B |
Intangibles | 11.8B |
Other Non-Current Assets | 10.5B |
Current Liabilities | 27.3B |
Accounts Payable | 2.6B |
Accrued Liabilities | 13.3B |
Other Current Liabilities | 11.4B |
Non-Current Liabilities | 25.9B |
Long-Term Debt | 18.3B |
Other Non-Current Liabilities | 7.6B |
Earnings Waterfall
Eli Lilly and Co
Revenue
|
34.1B
USD
|
Cost of Revenue
|
-7.1B
USD
|
Gross Profit
|
27B
USD
|
Operating Expenses
|
-16.7B
USD
|
Operating Income
|
10.3B
USD
|
Other Expenses
|
-5.1B
USD
|
Net Income
|
5.2B
USD
|
Free Cash Flow Analysis
Eli Lilly and Co
What is Free Cash Flow?
LLY Profitability Score
Profitability Due Diligence
Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
LLY Solvency Score
Solvency Due Diligence
Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for LLY is 843.06 USD with a low forecast of 545.4 USD and a high forecast of 1 050 USD.
Ownership
LLY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LLY Price
Eli Lilly and Co
Average Annual Return | 36.74% |
Standard Deviation of Annual Returns | 21.52% |
Max Drawdown | -10% |
Market Capitalization | 708.2B USD |
Shares Outstanding | 950 770 000 |
Percentage of Shares Shorted | 0.64% |
LLY News
Last Important Events
Eli Lilly and Co
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Eli Lilly and Co
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Contact
IPO
Employees
Officers
The intrinsic value of one LLY stock under the Base Case scenario is 342.38 USD.
Compared to the current market price of 745.95 USD, Eli Lilly and Co is Overvalued by 54%.